Cerebrolysin vs Semax
Neuropeptide Mixture (Porcine Brain Derived) · ACTH(4-10) Analog (Synthetic Peptide)
Here is how these two compounds compare, based on published research, not marketing claims.
Cerebrolysin
A porcine brain peptide preparation with international clinical trials across stroke, TBI, and dementia; administered by injection.
Semax
A defined synthetic heptapeptide upregulating BDNF/NGF; Russian-approved for nootropic use, administered nasally.
Cerebrolysin
658 studies
52 human trials
Not FDA-Approved
Semax
204 studies
10 human trials
Not FDA-Approved
What it does
Cerebrolysin
Delivers brain-repair signals into tissue that the bloodstream normally cannot reach. Made of short peptide fragments derived from pig brain tissue, small enough to cross the blood-brain barrier.
Semax
Increases brain-derived growth factors (BDNF and NGF) to support cognitive function, memory, and neuroprotection. Derived from a fragment of ACTH but engineered to have zero hormonal activity.
How it works
Cerebrolysin
Cerebrolysin is a mixture of low-molecular-weight neuropeptides and free amino acids produced by enzymatic breakdown of purified porcine brain proteins. The peptide fragments are small enough to cross the blood-brain barrier and mimic the activity of naturally occurring neurotrophic factors (BDNF, NGF, CNTF). Once in brain tissue, the fragments promote neuronal survival, stimulate synaptic plasticity, and support axonal growth and repair. The multi-target mechanism is the defining pharmacological feature: rather than hitting one receptor, cerebrolysin modulates several neuroprotective and neurorestorative pathways simultaneously.
Semax
Semax is a synthetic heptapeptide based on the ACTH (4-10) fragment with a Pro-Gly-Pro C-terminal extension that eliminates the adrenal hormonal effects of ACTH while preserving and enhancing the neuroprotective properties. It upregulates BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), two growth factors that drive synaptic plasticity, neuronal survival, and memory consolidation. Semax also modulates dopaminergic and serotonergic neurotransmission, contributing to attention and mood regulation.
How often
Cerebrolysin
Intravenous or intramuscular injection in clinical protocols across 40+ countries where cerebrolysin is approved. Published trials use multi-week treatment courses. Cerebrolysin is not FDA-approved in the United States; clinical availability in the U.S. does not exist through standard channels.
Semax
In Russian clinical practice, Semax is administered as a nasal spray for cognitive enhancement and stroke recovery. The compound received Russian regulatory approval. No FDA-approved product exists. Research protocols outside Russia primarily use nasal administration.
How strong
Cerebrolysin
Approved in more than 40 countries for stroke recovery, traumatic brain injury, and various forms of dementia. Large-scale clinical trials in stroke rehabilitation (CASTA, CARS) showed functional recovery benefits. The evidence base includes over 200 published studies with more than 50 human clinical trials. The strongest data is in acute ischemic stroke recovery and post-TBI rehabilitation, where multiple independent research groups have replicated findings.
Semax
Russian regulatory approval for nootropic and neuroprotective indications including stroke recovery. Published human studies document BDNF elevation, cognitive improvements, and neuroprotective effects in ischemic stroke patients. The compound has both preventive (cognitive support) and therapeutic (neuroprotection after injury) research applications.
Main tradeoff
Cerebrolysin
Internationally approved with decades of clinical use in stroke and TBI rehabilitation across more than 40 countries. Not FDA-approved in the United States; the specific U.S. trial package the FDA requires was never completed despite international clinical evidence. The 2013 Cochrane review found the evidence insufficient to draw definitive conclusions about efficacy in dementia, though subsequent trials have added data. Injectable-only delivery limits accessibility. As a porcine-derived biological product, batch-to-batch consistency and standardization are more complex than for synthetic peptides.
Semax
Same geographic evidence concentration as Selank: Russian regulatory approval with limited Western clinical replication. The BDNF and NGF elevation mechanisms are well-characterized, but controlled Western clinical trials are absent. Available through research peptide markets; not through standard Western clinical channels. Not FDA-approved for any indication.
Best for
Cerebrolysin
- Research interest in neuropeptide-based neuroprotection and neuroregeneration
- Research focused on stroke recovery, traumatic brain injury rehabilitation, or dementia where international clinical trial data applies
- Research comparing multi-target neuropeptide preparations versus single-target nootropic compounds
Semax
- Research on BDNF and NGF upregulation as a neuroprotective and nootropic strategy
- Research on ACTH-derived peptides engineered to separate neuroprotective from hormonal effects
- Research on peptide-based cognitive enhancement and post-stroke neuroprotection
How to choose
A good fit for Cerebrolysin
- Research on multi-target neuroprotective approaches with international clinical trial evidence
- Research on stroke recovery, traumatic brain injury, or Alzheimer's disease with published RCTs
- Research contexts where the breadth of international evidence matters
A good fit for Semax
- Research on defined single-molecule nootropic mechanisms (BDNF/NGF pathway)
- Research contexts where nasal administration is preferred
- Research on Russian-developed neuropeptide therapeutics with regulatory approval
Consider both across time
Cerebrolysin and Semax approach neuroprotection from complementary directions. Cerebrolysin delivers multiple neurotrophic peptide fragments by injection with international clinical validation. Semax delivers a single defined BDNF/NGF upregulator nasally with Russian clinical validation. The evidence geographies are complementary: Cerebrolysin has broader international recognition; Semax has deeper characterization as a single molecule. For the most comprehensive neuroprotective research context, both compounds contribute relevant data from different angles.
Dosing should be determined by a qualified physician who can evaluate individual circumstances. PSI does not provide personalized dosing guidance.
Official dosing references
- DailyMed(NIH drug labels)
- ClinicalTrials.gov
- PubMed
For readers who want the biology: here is the pathway each compound uses to signal the body. This section is optional. The comparison above covers the practical differences.
▶See the biology
- Blood-Brain Barrier Crossing
- Blood-Brain Barrier Crossing enables Neurotrophic Factor Mimicry
- Neurotrophic Factor Mimicry connects to Neuronal Survival
- Neurotrophic Factor Mimicry connects to Synaptic Plasticity
- Neurotrophic Factor Mimicry connects to Axonal Growth and Repair
- Neuronal Survival connects to Cognitive and Functional Recovery; Synaptic Plasticity connects to Cognitive and Functional Recovery; Axonal Growth and Repair connects to Cognitive and Functional Recovery
- BDNF Upregulation
- NGF Upregulation
- BDNF Upregulation modulates Dopaminergic Modulation
- BDNF Upregulation drives Synaptic Plasticity Enhancement; NGF Upregulation enables Synaptic Plasticity Enhancement
- Synaptic Plasticity Enhancement connects to Cognitive Function Support; Dopaminergic Modulation connects to Cognitive Function Support
- BDNF Upregulation supports Neuroprotection; NGF Upregulation supports Neuroprotection
Cerebrolysin's peptide fragments cross the blood-brain barrier to mimic neurotrophic factors that promote neuronal survival and synaptic plasticity.
Semax upregulates BDNF and NGF in the brain, driving synaptic plasticity and neuroprotection.
Research Evidence
Both compounds have substantial evidence, concentrated in different geographies. Cerebrolysin has multiple international RCTs across stroke, TBI, and Alzheimer's conducted in multiple countries. Semax has Russian regulatory approval with published human studies in stroke recovery and cognitive enhancement. The evidence overlap is in neuroprotection, but the approaches and validation frameworks differ.
- 1.
If the research interest is neuroprotection in clinical neurological populations (stroke, dementia), Cerebrolysin has the stronger and more independently replicated evidence base.
- 2.
If the research interest is self-administered nootropic peptides, Semax is the more relevant compound. Cerebrolysin requires injection and is not suitable for self-administration.
- 3.
If the research interest is multimodal neurotrophic support across multiple growth factor pathways simultaneously, Cerebrolysin's mixture profile is more relevant.
- 4.
If the research interest is BDNF-mediated cognitive activation in a single defined molecule, Semax provides a cleaner pharmacological model.
- 5.
Neither compound has established evidence for cognitive enhancement in healthy individuals, both evidence bases are concentrated in pathological populations.
Key Limitations
- •Neither compound is FDA-approved for any cognitive indication.
- •Cerebrolysin clinical trials were conducted primarily in pathological populations (stroke, dementia, TBI) not healthy individuals seeking cognitive enhancement.
- •Cerebrolysin's complex mixture composition makes precise mechanistic characterization more difficult than single-molecule peptides.
- •Cerebrolysin requires intramuscular or intravenous injection, not suitable for self-administration research contexts.
- •Semax's evidence base is concentrated in Russian-language literature with limited independent Western replication.
- •Long-term safety and efficacy data in healthy populations is absent for both compounds.
- •Translating clinical findings from neurological disease populations to healthy cognitive enhancement is not supported by current evidence for either compound.
Community Discussion
PSI monitors discussions across peptide research and biohacking communities. These are reported experiences, not clinical evidence.
Cerebrolysin
"Cerebrolysin is used in hospitals across Europe and Asia"
Supported by evidence
"Cerebrolysin improved my cognitive function after brain injury"
Plausible (clinical data exists)
Semax
"Semax improved my focus and cognitive performance"
Plausible but unproven
"It helped with my brain fog after COVID"
Anecdotal only
"The nasal version works within minutes"
Plausible but unproven
Safety Comparison
Both have favorable safety profiles. Cerebrolysin's safety is characterized from extensive international clinical trial programs (injection site reactions and mild headache most common). Semax's safety is characterized from Russian clinical use (non-sedating, no significant adverse effects). Neither is FDA-approved. Cerebrolysin's porcine origin has not raised clinically significant immunogenicity concerns in trial data.
Cerebrolysin
Approved in multiple countries for neurological conditions. Administered by intramuscular or intravenous injection. Favorable safety profile across a substantial body of clinical trial data. Rare hypersensitivity reactions documented. Not suitable for self-administration due to injection requirement.
Semax
Approved in Russia for cognitive impairment and stroke recovery. Favorable safety profile reported in Russian clinical data. Does not produce hormonal effects associated with full-length ACTH. Administered intranasally. Limited Western safety characterization.
What the Research Suggests
Cerebrolysin and Semax are not direct competitors, they serve different research contexts and have different practical profiles. Cerebrolysin has the stronger and more independently verified clinical evidence base, particularly for stroke and dementia populations, and is appropriately rated Human Trials contextual. Semax has a defined single-molecule mechanism and a practical administration advantage (intranasal vs injection), but a smaller and less independently replicated evidence base, rated Animal Studies. Researchers evaluating nootropic and neuroprotective peptides should treat these compounds as complementary rather than interchangeable, each is more relevant to a distinct research context.